Biological Response Modifiers Advisory Committee
July 22-23 meeting is cancelled and will be rescheduled for autumn. National Cancer Institute researcher Steven Rosenberg recently indicated that Cetus' Proleukin (interleukin-2) for renal cell carcinoma might be on the committee's agenda ("The Pink Sheet" May 27, In Brief); IL-2 failed to clear the committee nearly a year ago ("The Pink Sheet" Aug. 6, p. 6).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth